Autonomix Medical (NASDAQ: AMIX) is a development-stage medical device company with zero revenue, substantial net losses, a robust patent portfolio, and preclinical progress in nerve-sensing technology, attracting Strong Buy analyst ratings with high price targets despite extreme stock volatility and limited commercial traction.
Fact: Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas. It is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system via a catheter-based system with microchip-enabled sensing architecture to detect low-amplitude neural signals from within the vascular system.Yahoo Finance
Fact: The company's initial focus is on interventional chronic pain management associated with severe pancreatic cancer in a first-in-human proof-of-concept study (PoC 1), with expansion to PoC 2 for additional visceral cancers. Broader applications target chronic pain, hypertension, cardiovascular, and other nerve-related disorders.Company Website
Fact: The company holds exclusive rights to a rapidly growing global IP portfolio including 18 patent families and more than 120 issued or pending applications worldwide.Company Website
Interpretation: The technology aims to provide a "GPS for the nervous system" enabling precision-guided sense, treat, and verify approaches, which could differentiate it in interventional electrophysiology if clinical success is achieved.
Uncertainty: As a pre-commercial entity, the timeline to regulatory approval, commercialization, and revenue generation remains highly uncertain and dependent on successful clinical trials.
| Metric | Value | Source/Notes |
|---|---|---|
| Revenue (TTM / FY) | $0 | Development stage; no commercial sales Yahoo Finance |
| Net Income / Loss (TTM / FY2026) | Approximately -$16.7 million | Consistent across sources Yahoo Finance StockTitan |
| Operating Expenses (TTM) | Approximately $17.0 million | Primarily R&D and G&A Yahoo Finance |
| EPS (Basic, recent) | Large negative (e.g., around -$48.72 TTM in some reports; quarterly variations including beats/misses) | Highly variable due to share count changes and one-time items Yahoo Finance |
| Market Capitalization | Approximately $1.9M - $3.5M (varies with share price and outstanding shares ~971k) | Micro-cap classification Simply Wall St |
| Cash Position / Liquidity | Recent warrant inducement raised $2.6M (July 2026); current ratio reported strong in some analyses (~4.45) | Financing-dependent IR Site |
Interpretation: The company is entirely dependent on equity financings and has no revenue-generating products, leading to ongoing dilution risk and high burn rate.
Uncertainty: Exact share count and cash runway fluctuate with financings and clinical progress; detailed balance sheet data limited in summaries.
Fact: Consensus rating is Strong Buy based on 1-2 analysts (e.g., Maxim Group maintaining Buy rating as of February 17, 2026). Yahoo Finance Public.com
| Metric | Value | Notes |
|---|---|---|
| Average Price Target | ~$58.80 - $59.98 | Range: Low ~$42, High ~$75.60-$79.38 Yahoo Finance Investing.com |
| Number of Analysts | 1-2 | Limited coverage typical for micro-cap Public.com |
| Recommendation Breakdown | 100% Strong Buy / Buy | No Hold, Sell, or Underperform ratings reported Yahoo Finance |
Interpretation: High price targets imply substantial perceived upside based on clinical potential, but reflect the speculative nature of the stock.
Uncertainty: With minimal analyst coverage, ratings may not represent broad market consensus and can change quickly with new data or financings.
Fact: Competitors primarily consist of other small-cap or development-stage medical device companies in neurotech, sensing, ablation, or related fields. MarketBeat
| Company | Ticker | Focus Area | Notes |
|---|---|---|---|
| NeuroOne Medical Technologies | NMTC | Neural technologies / sensing | Similar neurotech space Yahoo Finance peers |
| Co-Diagnostics | CODX | Diagnostics / medtech | Often compared in small-cap medtech lists MarketBeat |
| Vivos Therapeutics | VVOS | Medical devices | Peer comparison MarketBeat |
| ENDRA Life Sciences | NDRA | Medical imaging / sensing | Peer MarketBeat |
| PAVmed | PAVM | Medical devices | Broad medtech peer MarketBeat |
| Others (e.g., Sonendo, HeartSciences, Quoin Pharma) | SONX, HSCS, QNRX | Various medtech | Common comparables MarketBeat |
Interpretation: Competition is from both larger players (e.g., Medtronic, Boston Scientific in ablation/denervation) and smaller innovators; Autonomix differentiates via its transvascular microchip sensing platform.
Uncertainty: Competitive landscape evolves with technological advances and clinical data; direct head-to-head comparisons are limited.
Interpretation: Recent news centers on IP expansion, preclinical validation, and financing, which are positive for a development-stage company but do not indicate near-term revenue.
Sources include Yahoo Finance, company website (autonomix.com / ir.autonomix.com), MarketBeat, Simply Wall St, and others linked above. For latest information, visit the linked resources.